According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain circumstancesREYKJAVIK, Iceland and TEL AVIV, Israel and PARSIPPANY, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of T

Aditum Bio, the biotech company creation firm from former Novartis leaders Joe Jimenez and Mark Fishman, has returned to China for another deal. This time, Aditum is forming a new company called Clavis Bio to develop medicines as part of a five-year collaboration with Fosun Pharma. The deal includes one of the largest milestone packages of the year. Details on the upfront payment remain undisclosed, but Clavis could eventually deliver up to $7.25 billion to its Shanghai-based partner, a Fosun sp

Guerbet announces the appointment of Mr. François Convenant as Senior Vice President of Interventional Radiology and his entry into the Executive Committee Villepinte, December 19, 2025: GUERBET (FR0000032526 GBT), a global player in medical imaging, announces the appointment of François Convenant as Senior Vice President of Interventional Radiology.In this role, he joins the Guerbet Group's Executive Committee (COMEX). This appointment marks an important milestone for Guerbet, confirming i

Staar Surgical, a manufacturer of the Implantable Collamer Lens, has delayed a shareholder vote on Alcon’s planned $1.6 billion takeover offer for the fourth time since October. In October, the vote was delayed until November 6, and was then pushed to December 3. The new vote is scheduled for January 6. Broadwood Partners, which holds 30.2% of Staar’s common shares, has advocated against the sale since the beginning, arguing that the deal undervalues the business and reflects a flawed sales proc

Proposed transaction aims to deliver near-term value for ProPhase shareholders, long-term growth for ABL, and create a global, innovation-driven company. PROPHASE LABS (NASDAQ:PRPH) ABL will gain enhanced access to U.S. capital markets and accelerate commercialization in the U.S. ABL’s international distribution network will support global expansion of ProPhase’s portfolio” — Dr Chalom B. Sayada LUXEMBOURG VILLE, LUXEMBOURG, December 19, 2025 / EINPresswire.com / -- Advanced Biological Laborator

PARIS, FRANCE, 19 December 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the pivotal Phase II FALKON trial did not meet its primary endpoint of reducing new heterotopic ossification (HO) in adults and children living with fibrodysplasia ossificans progressiva (FOP) vs. placebo, as a result the study will be closed. The investigational medicinal product (fidrisertib) was generally well tolerated, with no safety concerns in the trial. “These results are disappointing for the FOP c

BioMarin Pharmaceutical agreed to buy Amicus Therapeutics for $14.50 per share in cash, or approximately $4.8 billion, adding treatments for Fabry and Pompe to its rare disease portfolio. The deal, announced Friday, represents a 33% premium to Amicus' closing share price on Dec. 18 and has been approved by the boards of both companies. "Immediately upon close, this transaction is expected to accelerate BioMarin's revenue growth and strengthen our financial outlook," remarked CEO Alexander Hardy.

China appears to be outpacing the US in parts of biopharmaceutical innovation more quickly than previously understood, according to a new paper released Friday by the National Security Commission on Emerging Biotechnology (NSCEB).The analysis sharpens warnings first issued in April, when the commission concluded US policymakers had a three-year window to retain, or in some cases regain, leadership in biotechnology before risking long-term economic, military and technological disadvantages. That

Altimmune said Friday that its experimental drug pemvidutide continued to improve key non-invasive markers of fibrosis through 48 weeks in a mid-stage trial of patients with metabolic dysfunction-associated steatohepatitis (MASH), extending signals first seen at six months and clearing the way for Phase III testing next year.The Phase IIb IMPACT trial randomised 212 patients with biopsy-confirmed MASH and fibrosis stages F2/F3 with and without diabetes to receive either a 1.2 mg or 1.8 mg weekly

The FDA on Friday approved Cytokinetics' Myqorzo (aficamten), a cardiac myosin inhibitor for adults with symptomatic obstructive hypertrophic cardiomyopathy, giving the South San Francisco biotech its first marketed product. The decision follows a regulatory nod in China earlier this week, a first for the drug anywhere globally.The approval was based on results from the Phase III SEQUOIA-HCM study, which met its primary endpoint, improving peak oxygen uptake (pVO2) by 1.74 mL/kg/min compared to